A Phase 1/2 interventional study of ranibizumab 0.5 or 2.0 mg/0.05 cc in Polypoidal Choroidal Vasculopathy, sponsored by Southeast Retina Center, Georgia. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-12.
Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 1/2, and was the 7th registered.
55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.
Browse Polypoidal Choroidal Vasculopathy studies →1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 7–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 50 across 40 interventional studies indexed under Polypoidal Choroidal Vasculopathy.
Median enrollment 20 across the 12 interventional studies, 150 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Southeast Retina Center, Georgia has 3 studies filed under Polypoidal Choroidal Vasculopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month of drug safety follow up in subjects with exudative polypoidal choroidal vasculopathy (PCV) for a total of 24 months.
Twenty eyes will be randomized will receive 3 consecutive monthly intravitreal 1.0 or 2.0 mg/0.5mg (3:1 ratio) Ranibizumab injection with the first injection occuring at Day 0 and second and third injection occuring at month 1 and month 2 respectively. Retreatment with intravitreal Ranibizumab or other therapies will be at the investigators discretion but guidelines for recommended retreatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraocular injection of 1.0 or 2.0 mg/0.05 cc ranibizumab. Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met
Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc
Intraocular injection of 0.5 mg/0.05 cc ranibizumab. Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met
Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug page: RanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
Also known as: Lucentis
Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups.
Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more clinical macula (arcade to arcade), disease related vitreous hemorrhage, injection-related endophthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure - related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.
Time frame: 2 years
Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months
Time frame: 12 months
Change in Mean Central Foveal Thickness From Baseline
Time frame: 12 Months
Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months
Time frame: 12 Months
Number of Participants at Month 3 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame: 3 Months
Number of Participants at Month 6 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame: 6 months
Number of Participants at Month 9 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame: 9 Months
Number of Participants at Month 12 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame: 12 Months
Mean Change Best Corrected Visual Acuity at 4 Meters at Baseline, Month 3, Month 6, Month 9, and Month 12
Time frame: 12 months
Number of Participants at Month 3 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame: 3 months
Number of Participants at Month 6 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame: 6 months
Number of Participants at Month 9 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame: 9 months
Number of Participants at Month 12 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame: 12 months
| Milestone | Ranibizumab 1.0 or 2.0 mg (HIGH DOSE) | Ranibizumab 0.5 mg |
|---|---|---|
| Started | 15 | 5 |
| Completed | 15 | 5 |
| Not completed | 0 | 0 |
Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more clinical macula (arcade to arcade), disease related vitreous hemorrhage, injection-related endophthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure - related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.
| Adverse events | Control Group: Ranibizumab 0.5mg | Ranibizumab 1.0mg or 2.0mg |
|---|---|---|
| Total Ocular and Notable Systemic AEs | 4 | 24 |
| Blurred or decreased vision | 0 | 6 |
| Floaters | 2 | 4 |
| Dark Spots | 0 | 3 |
| Injection site or ocular pain | 0 | 2 |
| Increased Cataracts | 0 | 2 |
| Subretinal hemorrhage | 0 | 1 |
| Superior hemorrhage | 0 | 1 |
| Increased Choroidal Neovascularization | 0 | 1 |
| Corneal abrasion | 0 | 1 |
| Trace epiretinal membrane | 0 | 1 |
| Flashes | 0 | 1 |
| Progression of edema | 0 | 1 |
| Light sensitivity | 1 | 0 |
| Elevated blood pressure | 1 | 0 |
| letters | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months | 6.7 (-3 to 25) | -5 (-25 to 9) |
| um | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| Change in Mean Central Foveal Thickness From Baseline | -49.7 ± 100.71 | 94.4 ± 89.6 |
| mm^2 | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months | 2.38 (-1.12 to 8.71) | -0.38 (-1.12 to -0.02) |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5-9 letters | 3 | 0 |
| 10-14 letters | 2 | 0 |
| 15 letters or more | 3 | 0 |
| Less than 5 letters | 6 | 0 |
| Unevaluable | 1 | 0 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 3 | 1 |
| 10 letters | 1 | 0 |
| 15 or more letters | 4 | 0 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 3 | 0 |
| 10 letters | 3 | 0 |
| 15 letters | 2 | 0 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 4 | 1 |
| 10 letters | 1 | 0 |
| 15 letters | 3 | 0 |
| letters | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| Mean Change Baseline - M3 | 9.87 ± 15.27 | -2.8 ± 32.71 |
| Mean Change Baseline - M6 | 10.23 ± 33.51 | -3.6 ± 2.35 |
| Mean Change Baseline - M9 | 10.93 ± 43.81 | -6.8 ± 9.08 |
| Mean Change Baseline - M12 | 6.37 ± 26.02 | -7.3 ± 20.11 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 1 | 0 |
| 10 letters | 0 | 0 |
| 15 letters | 1 | 1 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 0 | 1 |
| 10 letters | 0 | 1 |
| 15 letters | 1 | 0 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 0 | 0 |
| 10 letters | 0 | 0 |
| 15 letters | 1 | 1 |
| Participants | Ranibizumab 2.0 mg | Ranibizumab 0.5 mg |
|---|---|---|
| 5 letters | 0 | 1 |
| 10 letters | 0 | 0 |
| 15 letters | 0 | 1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Group: Ranibizumab 0.5mg | — | 0/5 (0%) | 2/5 (40%) |
| Ranibizumab 1.0mg or 2.0mg | — | 0/15 (0%) | 9/15 (60%) |
| Event | Control Group: Ranibizumab 0.5mg | Ranibizumab 1.0mg or 2.0mg |
|---|---|---|
| Affected visionEye disorders | 1/5 | 6/15 |
| Elevated Blood pressureCardiac disorders | 1/5 | 0/15 |
| Intravitreal injection side effectsEye disorders | 0/5 | 2/15 |
| Increased cataractEye disorders | 0/5 | 2/15 |
| Superior hemorrhageEye disorders | 0/5 | 1/15 |
| Increased Choroidal neovascularizationEye disorders | 0/5 | 1/15 |
| Corneal AbrasionEye disorders | 0/5 | 1/15 |
| Trace epiretinal membraneEye disorders | 0/5 | 1/15 |
| Progression of edemaCardiac disorders | 0/5 | 1/15 |
| Age, Categorical(Participants) | Ranibizumab 1.0 or 2.0 mg (HIGH DOSE) | Ranibizumab 0.5 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 4 | 16 |
| >=65 years | 3 | 1 | 4 |
| Sex: Female, Male(Participants) | Ranibizumab 1.0 or 2.0 mg (HIGH DOSE) | Ranibizumab 0.5 mg | Total |
|---|---|---|---|
| Female | 7 | 2 | 9 |
| Male | 8 | 3 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Ranibizumab 1.0 or 2.0 mg (HIGH DOSE) | Ranibizumab 0.5 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 15 | 5 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ranibizumab 1.0 or 2.0 mg (HIGH DOSE) | Ranibizumab 0.5 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 1 | 8 |
| White | 7 | 4 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ranibizumab 1.0 or 2.0 mg (HIGH DOSE) | Ranibizumab 0.5 mg | Total |
|---|---|---|---|
| United States | 15 | 5 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2022, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Polypoidal Choroidal Vasculopathy →
Southeast Retina Center, Georgia